• Company
• Enhertu passes the DREC review in KOR
• by Eo, Yun-Ho Feb 5, 2024 05:54am

• Policy
• Reimb of Enhertu, Ilaris pass DREC review…deemed adequate
• by Lee, Tak-Sun Feb 5, 2024 05:53am

• InterView
• ‘Yuhan expects Leclaza’s FDA approval this year'
• by Kim, Jin-Gu Feb 5, 2024 05:52am

• Company
• New drugs and biosimilars to compete in the PNH market
• by Chon, Seung-Hyun Feb 2, 2024 12:28pm

• Company
• Ildong patents its new GLP-1 drug candidate in CN and JP
• by Lee, Seok-Jun Feb 2, 2024 12:28pm

• Company
• Roche’s Crovalimab receives Orphan Drug Designation in KOR
• by Eo, Yun-Ho Feb 2, 2024 12:28pm

• Policy
• Price of drugs listed in 2002-2006 may be adjusted next year
• by Lee, Tak-Sun Feb 2, 2024 12:28pm

• Company
• Onureg is now available in general hospitals
• by Eo, Yun-Ho Feb 1, 2024 12:39pm

• Company
• SK Biopharm’s new drug tops 500 bln won in US sales
• by Kim, Jin-Gu Feb 1, 2024 12:39pm

• Company
• Oral plaque psoriasis drug Sotyktu in final stages of reimb
• by Kim, Jin-Gu Feb 1, 2024 12:38pm